BIOMAT Database Logo BIOMAT Database Logo

Interstitial lung disease points to consider for clinical trials in systemic sclerosis. 2017

Dinesh Khanna, and James Seibold, and Jonathan Goldin, and Donald P Tashkin, and Daniel E Furst, and Athol Wells
Department of Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI.

Interstitial lung disease causes major morbidity and mortality in patients with systemic sclerosis (SSc-ILD). Large randomized clinical trials in SSc-ILD have provided important information regarding the feasibility, reliability and validity of outcome measures. Forced vital capacity percentage predicted should be considered as a primary outcome measure, with inclusion of appropriate radiological and patient-reported measures. We provide practical recommendations for trial design in SSc-ILD.

UI MeSH Term Description Entries
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012595 Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. Sclerosis, Systemic,Systemic Scleroderma,Systemic Sclerosis
D014943 Global Health A multi- and interdisciplinary field concerned with improving health and achieving equity in health for all people. It transcends national boundaries, promotes cooperation and collaboration within and beyond health science fields, and combines population-based disease prevention with individually-based patient care. International Health Problems,World Health,International Health,Worldwide Health,Health Problem, International,Health Problems, International,Health, Global,Health, International,Health, World,Health, Worldwide,Healths, International,International Health Problem,International Healths,Problem, International Health,Problems, International Health
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D017563 Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features. Diffuse Parenchymal Lung Disease,Diffuse Parenchymal Lung Diseases,Interstitial Lung Disease,Interstitial Lung Diseases,Pneumonia, Interstitial,Pneumonitis, Interstitial,Interstitial Pneumonia,Interstitial Pneumonias,Interstitial Pneumonitides,Interstitial Pneumonitis,Lung Disease, Interstitial,Pneumonias, Interstitial,Pneumonitides, Interstitial
D019468 Disease Management A broad approach to appropriate coordination of the entire disease treatment process that often involves shifting away from more expensive inpatient and acute care to areas such as preventive medicine, patient counseling and education, and outpatient care. This concept includes implications of appropriate versus inappropriate therapy on the overall cost and clinical outcome of a particular disease. (From Hosp Pharm 1995 Jul;30(7):596) Disease Managements,Management, Disease,Managements, Disease

Related Publications

Dinesh Khanna, and James Seibold, and Jonathan Goldin, and Donald P Tashkin, and Daniel E Furst, and Athol Wells
Muscle involvement in systemic sclerosis: points to consider in clinical trials.
September 2017, Rheumatology (Oxford, England),
Dinesh Khanna, and James Seibold, and Jonathan Goldin, and Donald P Tashkin, and Daniel E Furst, and Athol Wells
Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.
September 2017, Rheumatology (Oxford, England),
Dinesh Khanna, and James Seibold, and Jonathan Goldin, and Donald P Tashkin, and Daniel E Furst, and Athol Wells
Enrichment Strategies for Systemic Sclerosis-Interstitial Lung Disease Trials.
May 2024, American journal of respiratory and critical care medicine,
Dinesh Khanna, and James Seibold, and Jonathan Goldin, and Donald P Tashkin, and Daniel E Furst, and Athol Wells
Points to consider for designing trials in systemic sclerosis patients with arthritic involvement.
September 2017, Rheumatology (Oxford, England),
Dinesh Khanna, and James Seibold, and Jonathan Goldin, and Donald P Tashkin, and Daniel E Furst, and Athol Wells
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus.
April 2009, Annals of the rheumatic diseases,
Dinesh Khanna, and James Seibold, and Jonathan Goldin, and Donald P Tashkin, and Daniel E Furst, and Athol Wells
Points to consider for skin ulcers in systemic sclerosis.
September 2017, Rheumatology (Oxford, England),
Dinesh Khanna, and James Seibold, and Jonathan Goldin, and Donald P Tashkin, and Daniel E Furst, and Athol Wells
Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials.
March 2020, Journal of scleroderma and related disorders,
Dinesh Khanna, and James Seibold, and Jonathan Goldin, and Donald P Tashkin, and Daniel E Furst, and Athol Wells
Points to consider-Raynaud's phenomenon in systemic sclerosis.
September 2017, Rheumatology (Oxford, England),
Dinesh Khanna, and James Seibold, and Jonathan Goldin, and Donald P Tashkin, and Daniel E Furst, and Athol Wells
Enrichment strategies for clinical trials targeting skin fibrosis and interstitial lung disease in systemic sclerosis.
November 2023, Current opinion in rheumatology,
Dinesh Khanna, and James Seibold, and Jonathan Goldin, and Donald P Tashkin, and Daniel E Furst, and Athol Wells
Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials.
March 2020, Journal of scleroderma and related disorders,
Copied contents to your clipboard!